Back to Search Start Over

Efficacy and safety of Mojeaga remedy in combination with conventional oral iron therapy for correcting anemia in obstetric population: A phase II randomized pilot clinical trial

Authors :
George Uchenna Eleje
Ifeanyichukwu Uzoma Ezebialu
Joseph Tochukwu Enebe
Nnanyelugo Chima Ezeora
Emmanuel Onyebuchi Ugwu
Iffiyeosuo Dennis Ake
Ekeuda Uchenna Nwankwo
Perpetua Kelechi Enyinna
Chukwuemeka Chukwubuikem Okoro
Chika Prince Asuoha
Charlotte Blanche Oguejiofor
Ejeatuluchukwu Obi
Chigozie Geoffrey Okafor
Angela Ogechukwu Ugwu
Lydia Ijeoma Eleje
Divinefavour Echezona Malachy
Chukwunonso Emmanuel Ubammadu
Emeka Philip Igbodike
Chidebe Christian Anikwe
Ifeoma Clara Ajuba
Chinyelu Uchenna Ufoaroh
Richard Obinwanne Egeonu
Lazarus Ugochukwu Okafor
Chukwunonso Isaiah Enechukwu
Sussan Ifeyinwa Nweje
Onyedika Promise Anaedu
Odigonma Zinobia Ikpeze
Boniface Chukwuneme Okpala
Ekene Agatha Emeka
Chijioke Stanley Nzeukwu
Ifeanyi Chibueze Aniedu
Emmanuel Chidi Chukwuka
Arinze Anthony Onwuegbuna
David Chibuike Ikwuka
Chisom God’swill Chigbo
Chiemezie Mac-Kingsley Agbanu
Chidinma Ifechi Onwuka
Malarchy Ekwunife Nwankwo
Henry Chinedu Nneji
Kosisochukwu Amarachukwu Onyeukwu
Boniface Uwaezuoke Odugu
Sylvester Onuegbunam Nweze
Ifeanyi Johnson Onyekpa
Kenneth Chukwudi Eze
Shirley Nneka Chukwurah
Joseph Odirichukwu Ugboaja
Joseph Ifeanyichukwu Ikechebelu
Source :
PLOS ONE. 18:e0285474
Publication Year :
2023
Publisher :
Public Library of Science (PLoS), 2023.

Abstract

Background To our knowledge, there is no prior randomized trial on the efficacy of Mojeaga remedy (a special blend of Alchornea cordifolia, Pennisetum glaucum and Sorghum bicolor extracts) when co-administered with standard-of-care for correction of anemia in obstetrics practice. This study determined the efficacy, safety and tolerability of Mojeaga as adjunct to conventional oral iron therapy for correction of anemia in obstetric population. Methods A pilot open-label randomized clinical trial. Participants with confirmed diagnosis of anemia in three tertiary hospitals in Nigeria were studied. Eligible participants were randomized 1:1 to either Mojeaga syrups 50 mls (200mg/50mls) administered three times daily in conjunction with conventional iron therapy (Mojeaga group) for 2 weeks or conventional iron therapy alone without Mojeaga (standard-of-care group) for 2 weeks. Repeat hematocrit level were done 2 weeks post-initial therapy. Primary outcome measures were changes in hematocrit level and median hematocrit level at two weeks post therapy. Maternal adverse events and neonatal outcomes (birth anomalies, low birthweight, preterm rupture of membranes and preterm labor) were considered the safety outcome measures. Analysis was by intention-to-treat. Results Ninety five participants were enrolled and randomly assigned to the Mojeaga group (n = 48) or standard-of-care group (n = 47). The baseline socio-demographic and clinical characteristics of the study participants were similar. At two weeks follow-up the median rise in hematocrit values from baseline (10.00±7.00% vs 6.00±4.00%;p0.05). Conclusion Mojeaga represents a new adjuvants for standard-of-care option for patients with anemia. Mojeaga remedy is safe for treating anemia during pregnancy and puerperium without increasing the incidence of congenital anomalies, or adverse neonatal outcomes. Clinical trial registration www.pactr.samrc.ac.za: PACTR201901852059636 (https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=5822).

Subjects

Subjects :
Multidisciplinary

Details

ISSN :
19326203
Volume :
18
Database :
OpenAIRE
Journal :
PLOS ONE
Accession number :
edsair.doi...........f03ceeb45850790126251c1e4824ccda
Full Text :
https://doi.org/10.1371/journal.pone.0285474